Ferric Maltol
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Iron Deficiency, Anaemia in Children
Conditions
Iron Deficiency, Anaemia in Children, Iron-Deficiency
Trial Timeline
Mar 14, 2017 → Mar 28, 2018
NCT ID
NCT03181451About Ferric Maltol
Ferric Maltol is a phase 1 stage product being developed by Medpace for Iron Deficiency, Anaemia in Children. The current trial status is completed. This product is registered under clinical trial identifier NCT03181451. Target conditions include Iron Deficiency, Anaemia in Children, Iron-Deficiency.
What happened to similar drugs?
5 of 13 similar drugs in Iron Deficiency, Anaemia in Children were approved
Approved (5) Terminated (0) Active (8)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03181451 | Phase 1 | Completed |
Competing Products
20 competing products in Iron Deficiency, Anaemia in Children
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KER-047 | Keros Therapeutics | Phase 2 | 17 |
| H. pylori treatment | Eisai | Phase 2/3 | 38 |
| Deferasirox | Novartis | Phase 3 | 40 |
| CSJ137 + Placebo | Novartis | Phase 1 | 29 |
| Deferasirox and Deferoxamine | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 2 | 35 |
| ICL670 | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Approved | 43 |
| Deferasirox + Deferasirox | Novartis | Phase 2/3 | 38 |
| Desferasirox | Novartis | Approved | 43 |
| Deferasirox | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 3 | 40 |
| Deferasirox dispersible tablet + Defearisox film-coated tablet | Novartis | Phase 2 | 35 |
| deferasirox | Novartis | Approved | 43 |
| Deferasirox (ICL670) | Novartis | Phase 1/2 | 32 |
| ICL670 | Novartis | Approved | 43 |
| Deferasirox | Novartis | Phase 3 | 40 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Approved | 43 |
| Z-213 + Saccharated Ferric Oxide | Zeria Pharmaceutical | Phase 3 | 40 |